Leading Japanese CRO Partners with Medidata Solutions Through ASPire to Win Program

Puntúa la noticia :

Nota de los usuarios: - (0votos)

Share

Tweet

elEconomista.es en Twitter

Follow @eleconomistaes

EcoTablet - ¡Gratis en App Store!

La plataforma más completa de información y servicios económicos para iPad.

• Suscribirse al boletín
• Imprimir
• Enviar
• Aumentar texto
• Reducir texto
• Haga doble click sobre una palabra para ver su signifcado
• Sudoku: Juega cada día a uno nuevo
• El tiempo: Consulta la previsión para tu ciudad

Medidata Solutions, a global provider of electronic clinical data
capture (EDC), management and reporting solutions, today announced the
start of its ASPire to Win(TM) partnership with EPS, one of Japan's
largest contract research organizations (CRO). As the first ASPire to
Win partner in Japan, EPS can now easily incorporate Medidata Rave(R)
into their existing offerings to manage electronic clinical trial data
for biopharmaceutical and medical device companies around the world.

Established in 1991, EPS provides a full range of professional
services in clinical trials for drug development to pharmaceutical
companies in Japan. EPS selected Medidata Rave due to increased
sponsor demand for the product's robust functionality, ease-of-use and
integration capabilities. By participating in Medidata's ASPire to Win
Program, a non-exclusive application service provider (ASP)
partnership and business model, EPS can offer Medidata Rave in-house
and create new services revenue around the implementation of this
industry-leading technology.

"At EPS, we have trust in Medidata due to the company's growing
market presence in Japan and globally. We respect the company's
ability to support global studies through Rave's multi-lingual
capabilities and manage clinical trial data in a single, secure and
scalable system," said Hisao Imamura, Senior Manager in the office of
the president at EPS. "We look forward to working with Medidata to
provide the strongest EDC and CRO services available to customers in
the demanding Japan market."

Since the trend toward clinical research outsourcing is still new
in Japan, there are many challenges to address to meet the increasing
customer needs for both quality and quantity of services. Through
implementing Medidata Rave, EPS will accelerate their new business of
global studies. Additionally, with the greater ability to streamline
clinical data collection and management for its clients, the Rave
certification will allow EPS to continue to expand their offerings for
sponsors.

"As one of Japan's largest CROs, EPS maintains a proven ability to
contribute to better pharmaceutical product development, and the
company's decision to implement Medidata Rave into their existing EDC
solution will help facilitate the constant growth of Rave in Japan -
and around the globe," said Tarek Sherif, CEO at Medidata Solutions.
"We look forward to furthering the success of EPS' new and existing
customers through Medidata's ASPire to Win Program."

About EPS

EPS is a CRO (contract research organization) that operates
clinical trials precisely, rapidly and objectively. We provide a full
range of professional services in Japan, China and Southeast Asia. We
are supporting entire drug development with SMO, IT and global
business. For more information, please visit www.eps.co.jp/.

About Medidata Solutions Worldwide

Medidata Solutions helps the world's leading pharmaceutical,
biotechnology, medical device and research organizations maximize the
value of their clinical research investments. Innovative process
design, technology and services streamline clinical trials by
providing early visibility to reliable clinical data - the lifeblood
of every research organization. Working with companies and
institutions both large and small, Medidata Solutions helps clinical
researchers safely accelerate the process of bringing life-enhancing
treatments to market - on six continents and in more than 80
countries. Medidata Solutions brings significant value to its broad
client base with deep clinical experience and expertise in more than
20 therapeutic areas, projects in Phase I, II, III, IV, registries and
surveillance, and studies with thousands of investigators and
tens-of-thousands of subjects. For more information, please visit
www.mdsol.com.

PUBLICIDAD

- Recibe nuestros análisis Diarios sobre Divisas, Acciones y Opciones. ¡Apúntate ya! ¡Es GRATIS!

- Opere en más de 8.000 CFDs. Infórmese y obtenga su CFD Trading Guide

- Nuevos spreads en materias primas: Oro tan sólo 0,3 puntos, Plata 0,25, Petróleo 0,35

- Opera desde 2,95 € en tiempo real con Self Bank.